Researchers have identified immune cell gene expression signatures that could one day be developed into tests to predict response to treatment.
Researchers tested the combined treatment in mice, after detecting increased PAK4 expression and reduced immune infiltration in melanoma patients with poor anti-PD-1 response.
The company is developing dedicated product lines for next-generation sequencing that incorporate a thermal cycler capable of 35-minute PCR.
The deal will focus on Biocartis' Idylla MSI test, which provides information on a tumor's microsatellite instability status of a tumor from a single FFPE slice.
In Nature this week: genomic factors that influence glioblastoma response to anti-PD-1 therapy, sequencing test for infectious disease, and more.
The researchers will not only explore tissue and circulating biomarkers but also the role of the microbiome in predicting benefit from immune checkpoint inhibitors.
H3, a subsidiary of Japanese drugmaker Eisai, is developing personalized cancer treatments targeting genomic alterations, including aberrant RNA splicing.
During the meeting, researchers presented studies on combination immunotherapies and the efficacy of giving molecularly-informed treatments earlier in the disease continuum.
The trial will test two Bristol-Myers Squibb cancer drugs in patients with metastatic or unresectable tumors harboring mutations in the genes POLE and POLD1.
The pharma company plans to use the Signatera assay to determine whether it can identify patients who will respond to immunotherapy.
Rady Children's Institute for Genomic Medicine and Deloitte are looking into the use of drones to transport samples for testing.
Direct-to-consumer genetic testing firm 23andMe is laying off about 100 people.
Researchers from Northwestern University examined dust for antibiotic-resistance genes, New Scientist reports.
In Science this week: researchers present a computational method for predicting cellular differentiation state from single-cell RNA sequencing data, and more.